Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes

Show full item record



Permalink

http://hdl.handle.net/10138/234041

Citation

Ritzel , R , Roussel , R , Giaccari , A , Vora , J , Brulle-Wohlhueter , C & Yki-Järvinen , H 2018 , ' Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes ' , Diabetes, obesity and metabolism , vol. 20 , no. 3 , pp. 541-548 . https://doi.org/10.1111/dom.13105

Title: Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes
Author: Ritzel, Robert; Roussel, Ronan; Giaccari, Andrea; Vora, Jiten; Brulle-Wohlhueter, Claire; Yki-Järvinen, Hannele
Contributor: University of Helsinki, Department of Medicine
Date: 2018-03
Language: eng
Number of pages: 8
Belongs to series: Diabetes, obesity and metabolism
ISSN: 1462-8902
URI: http://hdl.handle.net/10138/234041
Abstract: AimsTo investigate the efficacy and safety of insulin glargine 300U/mL (Gla-300) vs insulin glargine 100U/mL (Gla-100) over 12months in a patient-level meta-analysis, using data from the EDITION studies in people with type 2 diabetes (T2DM). Methods EDITION 1, 2 and 3 were multicentre, randomized, open-label, 2-arm, parallel-group, treat-to-target phase IIIa studies. Similar study designs and endpoints enabled a meta-analysis to be conducted. ResultsReductions in glycated haemoglobin (HbA1c) were better sustained over 12months with Gla-300 than with Gla-100 (least squares [LS] mean difference in change from baseline: -0.10 % [95% confidence interval {CI} -0.18 to -0.02] or -1.09mmol/mol [95% CI -2.01 to -0.20]; P=.0174). Risk of confirmed (3.9mmol/L) or severe hypoglycaemia was 15% lower with Gla-300 vs Gla-100 at night (relative risk 0.85 [95% CI 0.77-0.92]) and 6% lower at any time of day (relative risk 0.94 [95% CI 0.90-0.98]). Rates of hypoglycaemia were 18% lower with Gla-300 vs Gla-100 at night (rate ratio 0.82 [95% CI 0.67-0.99]), but comparable at any time of day. HbA1c ConclusionsIn a broad population of people with T2DM over 12months, use of Gla-300 provided more sustained glycaemic control and significantly lower hypoglycaemia risk at night and at any time of day compared with Gla-100.
Subject: glycaemic control
hypoglycaemia
insulin analogues
meta-analysis
phase III study
type 2 diabetes
ORAL ANTIHYPERGLYCEMIC DRUGS
INCLUDING 6-MONTH EXTENSION
GLUCOSE CONTROL
BASAL INSULIN
TRIAL
UNITS/ML
ASSOCIATION
RESISTANCE
ADHERENCE
ADULTS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Ritzel_et_al_20 ... esity_and_Metabolism_1.pdf 762.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record